上海谊众：预计2025年净利润同比增长760.18%—903.54%

Core Viewpoint - Shanghai Yizhong (688091) expects a significant increase in net profit for the year 2025, projecting a range of 60 million to 70 million yuan, which represents a year-on-year growth of 760.18% to 903.54% [1] Group 1 - The company's core product, injectable paclitaxel polymer micelles (referred to as "paclitaxel micelles"), will be officially included in the national medical insurance directory in 2025 [1] - The inclusion in the medical insurance directory is expected to substantially increase market access and the number of patients using the product, leading to significant growth in both revenue and profit compared to 2024 [1]